Benralizumab Associated with Fewer Exacerbations in Severe Asthma with Eosinophilia (FREE)

By Kelly Young Edited by David G. Fairchild, MD, MPH Benralizumab, an anti-interleukin-5 pathway monoclonal antibody, is associated with 28% to 51% fewer exacerbations of severe eosinophilic asthma, according to two industry-conducted, phase III studies presented at the European Respiratory Society meeting and published in the Lancet.In the SIROCCO trial, 1200 patients with asthma who …

http://ift.tt/2cv0wF5